Producing Homogeneous Antibody Drug Conjugates with Combination Warheads
Presented by Aaron K. Sato, Sutro Biopharma
Cell–free protein synthesis methods have been developed for production of homogeneous therapeutic proteins, including Antibody Drug Conjugates (ADCs). Many variants can be expressed in hours and rapidly assessed for function. Within days, production of chosen variants can be scaled using the same platform to generate material for clinical studies. The power and utility of the platform to design and manufacture single species antigen-targeted combination warheads will be described. In particular, the stability and pharmacokinetics of these homogeneous ADCs will also be highlighted.